Finally, we investigated whether RhoA/ROCK2 pathway inhibition using fasudil, a widely used ROCK2 inhibitor, has therapeutic effects on cognitive impairment and synaptic deficits following CSR. This evidence concerns the gene RHOA and Cognitive impairment.